• AAPL 195.71
  • TSLA 243.84
  • AMZN 147.42
  • BTC-USD 44102.2734
  • ETH-USD 2363.7668
  • EURUSD 1.0764
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. IVA.US

Inventiva Sa (IVA NASDAQ) stock market data APIs

$4.55 0(0%) as of December 8, 2023

Inventiva Sa Financial Data Overview

4.55
4.55
-
4.55
4.55
2.22-6.82
235 M
51 647 K
22 044 K
-0.53
0
0.914
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'IVA',
Type: 'Common Stock',
Name: 'Inventiva Sa',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00VM4C335',
ISIN: NULL,
CUSIP: NULL,
CIK: '1756594',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2020-07-10',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
GicSector: 'Health Care',
GicGroup: 'Pharmaceuticals, Biotechnology & Life Sciences',
GicIndustry: 'Biotechnology',
GicSubIndustry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Inventiva Sa Fundamental Data is available in our Financial Data APIs

  • Net Revenue 22 044 K
  • EBITDA -77 273 000
  • Earnings Per Share -2.05
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Inventiva Sa Earnings via APIs

  • Latest Release 2023-11-21
  • EPS/Forecast -0.5

Get Inventiva Sa End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Inventiva Sa latest news via APIs

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

INVENTIVA The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety data The safety assessment was based on the review of safe...

Inventiva reports 2023 Third Quarter Financial Information¹

INVENTIVA Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 30, 2023, compared to €86.7 million, €1.0...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com